Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide

Cancer

Volumn 103, Issue 11, 2005, Pages 2287-2297

  Hoskin, Peter J ^a   Rojas, Ana M ^a   Phillips, Heather ^a   Saunders, Michele I ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Acute morbidity; Bladder carcinoma; Carbogen; Late morbidity; Nicotinamide

Indexed keywords

CARBOGEN; NICOTINAMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CARCINOGENESIS; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DYSURIA; FEMALE; HEMATURIA; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NOCTURIA; PRIORITY JOURNAL; TREATMENT OUTCOME; URINARY DYSFUNCTION; URINARY FREQUENCY; URINARY URGENCY;

ADULT; AGED; AGED, 80 AND OVER; CARBON DIOXIDE; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CELL HYPOXIA; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MIDDLE AGED; NIACINAMIDE; OXYGEN; RADIOTHERAPY, HIGH-ENERGY; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 18844420781     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21048     Document Type: Article

References (28)

1. Brown JM. Evidence for acutely hypoxic cells in mouse tumours and a possible mechanism of reoxygenation. Br J Radiol. 1979;52:650-656.
2. Chaplin DJ, Horsman MR, Aoki DS. Nicotinamide, fluosol DA and carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br J Cancer. 1991;63:109-113.
3. Kjellen E, Joiner MC, Collier JM, Johns H, Rojas A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol. 1991;22:81-91.
4. Rojas A, Hirst VK, Calvert AS, Johns H. Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy. Int J Radiat Oncol Biol Phys. 1996;34:357-365.
5. Rojas A, Vojnovic B, Johns H, et al. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated X-ray schedules. Radiother Oncol. 1996;39:53-64.
6. Rojas A. ARCON: accelerated radiotherapy with carbogen and nicotinamide. Br J Radiol. 1992;24:174-178.
7. Overgaard J. Modification of hypoxia - from Gottwald Schwarz to nicotinamide. Have we learned the lesson? In: Kogelnik HD, editor. Progress in radio-oncology. Bologna: Monduzzi Editore, 1995:469-475.
8. Hoskin PJ, Saunders MI, Phillips H, et al. Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br J Cancer. 1997;76:260-263.
9. Kaanders JH, Pop LA, Marres HA, et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol. 1998;48:115-122.
10. Saunders MI, Hoskin PJ, Pigott K, et al. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study. Radiother Oncol. 1997;45:159-166.
11. Kaanders JH, Pop LA, Marres HA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:769-778.
12. Dische S. What have we learnt from hyperbaric oxygen? Radiother Oncol. 1991;20:71-74.
13. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the bladder primarily treated by radical mega voltage X-ray therapy. Radiother Oncol. 1986;7:299-310.
14. Gospodarowicz MK, Rider W, Keen CW, et al. Bladder cancer: long term follow-up results of patients treated with radical radiation. Clin Oncol. 1991;3:155-161.
15. Hoskin PJ, Stratford MRL, Saunders MI, Hall DW, Dennis MF, Rojas A. Administration of nicotinamide during CHART: pharmacokinetics, dose escalation, and clinical toxicity. Int J Radiat Oncol Biol Phys. 1995;32:1111-1119.
16. Stratford MRL, Dennis MF, Hoskin PJ, Saunders MI, Hodgkiss RJ, Rojas A. Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. Acta Oncol. 1996;35:213-219.
17. Dische S, Rojas A, Rugg T, Hong A, Michael BD. Carbogen breathing: a system for use in man. Br J Radiol. 1992;65:87-90.
18. Powell ME, Collingridge DR, Saunders MI, Hoskin PJ, Hill SA, Chaplin DJ. Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol. 1999;50:167-171.
19. Dische S, Warburton MF, Jones D, Lartigau E. The recording of morbidity related to radiotherapy. Radiother Oncol. 1989;16:103-108.
20. Borgaonkar S, Jain A, Bollina P, et al. Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique. Clin Oncol. 2002;14:141-147.
21. Lynch WJ, Jenkins BJ, Fowler CG, Hope-Stone HF, Blandy JP. The quality of life after radical radiotherapy for bladder cancer. Br J Urol. 1992;70:519-521.
22. Edsmyr F, Andersson L, Esposti PL, Littbrand B, Nilsson B. Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radiother Oncol. 1985;4:197-203.
23. Jahnson S, Pedersen J, Wesman G. Bladder carcinoma a 20-year review of radical irradiation therapy. Radiother Oncol. 1991;22:111-117.
24. Perez CA, Brady LW. Overview. In: Perez CA, Brady LW, editors. Principles and practice of radiation oncology. Philadelphia: Lippincott, 1992:1-63.
25. Mornex F, Pavy JJ, Denekamp J, Bolla M. Scoring system of late effects of radiation on normal tissues: the SOMA-LENT scale. Cancer Radiother. 1997;1:622-668.
26. Maciewjewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol. 1991;21:163-170.
27. de Neve W, Lybeert MLM, Goor C, Crommelin MA, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol. 1995;36:183-188.
28. Moonen L, van de Voet H, Horenblas S, Bartelink H. A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys. 1997;37:537-542.